WO2015129893A1 - Composition pharmaceutique pour administration orale - Google Patents

Composition pharmaceutique pour administration orale Download PDF

Info

Publication number
WO2015129893A1
WO2015129893A1 PCT/JP2015/055976 JP2015055976W WO2015129893A1 WO 2015129893 A1 WO2015129893 A1 WO 2015129893A1 JP 2015055976 W JP2015055976 W JP 2015055976W WO 2015129893 A1 WO2015129893 A1 WO 2015129893A1
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical composition
oral administration
acceptable salt
pharmaceutically acceptable
mirabegron
Prior art date
Application number
PCT/JP2015/055976
Other languages
English (en)
Japanese (ja)
Inventor
筒井　勇樹
敬康 豊田
正志 箱守
Original Assignee
アステラス製薬株式会社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アステラス製薬株式会社 filed Critical アステラス製薬株式会社
Publication of WO2015129893A1 publication Critical patent/WO2015129893A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the present invention includes mirabegron or a pharmaceutically acceptable salt thereof, a release controlling part for controlling this release, and solifenacin or a pharmaceutically acceptable salt thereof for immediate release for prompt release.
  • the present invention relates to a pharmaceutical composition for oral administration. Specifically, the present invention relates to 1) a controlled release portion comprising 1) mirabegron or a pharmaceutically acceptable salt thereof, a macromolecular substance forming a hydrogel, and a hydrophilic base, and 2) a) solifenacin or a thereof. Oral administration comprising a pharmaceutically acceptable salt and b) an immediate release part containing mirabegron or a pharmaceutical additive that improves the stability of the pharmaceutically acceptable salt in a single preparation.
  • the present invention relates to a pharmaceutical composition for use.
  • Mirabegron is a compound represented by the following chemical structural formula, and mirabegron or a pharmaceutically acceptable salt thereof has a ⁇ 3 adrenergic receptor agonistic action and is useful as a therapeutic agent for overactive bladder.
  • Patent Document 1 Patent Document 2, Patent Document 3).
  • tablets containing mirabegron are sold as therapeutic agents for overactive bladder.
  • Patent Document 4 It has been reported that the pharmacokinetics fluctuates depending on the presence or absence of food intake in clinical trials conducted at the development stage of mirabegron (Patent Document 4). If the pharmacokinetics fluctuates depending on the presence or absence of food intake, it naturally affects its action and effect. In particular, in the case of pharmaceuticals, if an effect that is different from the prediction is generated, an unexpected situation may be caused, so that it is necessary to be able to predict a certain effect. Therefore, there is a strong demand for the development of drugs that minimize the fluctuations in pharmacokinetics with and without food intake. The changes in pharmacokinetics with and without food intake in mirabegron are related to drug release using various additives. It is known that it can be reduced by control (Patent Document 4).
  • Solifenacin is a compound represented by the following chemical structural formulas, solifenacin or a pharmaceutically acceptable salt thereof has a selective antagonistic action against muscarine M 3 receptors, various disease prevention and / or It is known to be useful as a therapeutic agent (Patent Document 5).
  • Tablets containing solifenacin succinate as solifenacin or a pharmaceutically acceptable salt thereof are sold as a therapeutic agent for overactive bladder.
  • composition containing mirabegron or a pharmaceutically acceptable salt thereof for improving urinary urgency, frequent urination and / or urinary incontinence associated with overactive bladder, and solifenacin or a pharmaceutically acceptable salt thereof An invention relating to a pharmaceutical composition containing a salt and a combination thereof is disclosed (Patent Document 6).
  • tamsulosin or a pharmaceutically acceptable salt thereof a release control part containing a hydrophilic substance and a polymer material forming a hydrogel, solifenacin or a pharmaceutically acceptable salt thereof and a hydrophilic substance
  • a pharmaceutical composition for oral administration is known that contains a rapid-release part in a single preparation (Patent Document 7).
  • Patent Document 8 a stable particulate pharmaceutical composition using solifenacin or a salt thereof and a specific binder, a method for producing the same, an orally disintegrating tablet containing the particulate pharmaceutical composition, and the stability of the particulate pharmaceutical composition
  • Patent Document 8 A technique related to the conversion method is known (Patent Document 8). This technique is an invention relating to a stable particulate pharmaceutical composition of solifenacin or a salt thereof.
  • An object of the present invention is to provide a single preparation comprising a controlled-release part containing mirabegron or a pharmaceutically acceptable salt thereof and an immediate-release part containing solifenacin or a pharmaceutically acceptable salt thereof (Providing a single formulation (mixture) that suppresses the generation of related substances during storage of each drug, and suppresses changes in the dissolution rate of mirabegron during storage. Is to provide a single preparation (mixture).
  • Example 10 of Patent Document 4 A single preparation (bilayer tablet) was prepared using the same component as the immediate-release part containing solifenacin succinate (Comparative Example 1 described later).
  • solifenacin succinate Comparative Example 1 described later.
  • solubility of solifenacin succinate in water is 610 mg / mL
  • solubility in the second solution of the Japanese Pharmacopoeia Dissolution Test (pH 6.8) is 430 mg / mL
  • solubility expression of the Japanese Pharmacopoeia is expressed as succinic acid.
  • Solifenacin is classified as a substance that is easily soluble in neutral solvents such as water.
  • the present inventors surprisingly conducted a further diligent study focusing on the suppression of mirabegron and solifenacin succinate related substance generation, and the suppression of the change in the dissolution rate of mirabegron from the release control part during storage.
  • (A) Preventing the generation of mirabegron-related substances contained in the release control part by increasing the crystallinity of the pharmaceutical additive contained in the immediate-release part (including the seed crystal (seed crystal) formulation) What can be done, (b) prevent changes in the dissolution rate of mirabegron contained in the release control part by increasing the crystallinity of the pharmaceutical additive contained in the immediate release part (including the seed crystal (seed crystal) formulation)
  • the present invention has been completed. It has also been found that the same effect can be obtained by adding a water-soluble polymer to the immediate release part.
  • the present invention [1] (1) A controlled release part containing mirabegron or a pharmaceutically acceptable salt thereof, (2) solifenacin or a pharmaceutically acceptable salt thereof, and mirabegron or a pharmaceutically acceptable salt thereof A pharmaceutical composition for oral administration, comprising an immediate release part containing a pharmaceutical additive that improves the stability of the salt, [2] The pharmaceutical composition for oral administration according to [1], wherein the pharmaceutical additive that improves the stability of mirabegron or a pharmaceutically acceptable salt thereof is a crystalline saccharide and / or a water-soluble polymer.
  • composition for oral administration according to [1] or [2], wherein the pharmaceutical additive that improves the stability of mirabegron or a pharmaceutically acceptable salt thereof is a crystalline saccharide, [4]
  • the blending ratio of the pharmaceutical additive that improves the stability of mirabegron or a pharmaceutically acceptable salt thereof is about 0.3% by weight or more and about 99% by weight or less with respect to the weight of the immediate release part.
  • composition for [13] The pharmaceutical composition for oral administration according to any one of [1] to [12], wherein the release control part further comprises an additive for allowing water to enter the inside of the release control part
  • the release control part further comprises an additive for allowing water to enter the inside of the release control part
  • the additive for allowing water to enter the inside of the release control part has a solubility in which the amount of water dissolving 1 g is 10 mL or less
  • the ratio of the additive for causing water to enter the inside of the release control unit is about 5% by weight or more and about 75% by weight or less based on the weight of the release control unit.
  • a pharmaceutical composition for oral administration [16] The pharmaceutical composition for oral administration according to any of [1] to [15], wherein the pharmaceutical composition is a pharmaceutical composition for improving urgency, frequent urination and / or urinary incontinence associated with overactive bladder , [17] The pharmaceutical composition for oral administration according to any one of [1] to [16], wherein the pharmaceutical composition is a tablet, [18] The pharmaceutical composition for oral administration according to any one of [1] to [17], wherein the tablet is a multilayer tablet, [19] The pharmaceutical composition for oral administration according to any one of [1] to [18], wherein the tablet is a bilayer tablet, [20] (1) A layer containing mirabegron or a pharmaceutically acceptable salt thereof, and (2) a layer containing solifenacin or a pharmaceutically acceptable salt thereof, and a crystalline saccharide and / or a water-soluble polymer.
  • a pharmaceutical composition for oral administration comprising [21] (1) A layer containing mirabegron or a pharmaceutically acceptable salt thereof, and (2) a layer containing solifenacin or a pharmaceutically acceptable salt thereof, and a crystalline sugar and / or a water-soluble polymer. Or a pharmaceutical composition for oral administration, comprising mirabegron or a water-soluble polymer thereof according to (2) solifenacin or a pharmaceutically acceptable salt thereof.
  • a method of stabilizing a pharmaceutically acceptable salt Is to provide.
  • a single preparation comprising a controlled release part containing mirabegron or a pharmaceutically acceptable salt thereof and an immediate release part containing solifenacin or a pharmaceutically acceptable salt thereof ( (Combinations) can be provided to clinical sites, and a single formulation (combination) that suppresses the formation of related substances during storage of each drug can be provided, and changes in the dissolution rate of mirabegron during storage It is possible to provide a single preparation (mixture) that suppresses the above.
  • solifenacin or a pharmaceutically acceptable salt thereof By blending calcium stearate in the immediate-release part containing solifenacin or a pharmaceutically acceptable salt thereof, a single formulation (similar formulation having a rapid release of solifenacin compared to the current formulation (single agent)) A mixture) can be provided.
  • the solifenacin succinate layer of the pharmaceutical composition for oral administration (bilayer tablet) prepared in Example 1 and Reference Example 1
  • the solifenacin succinate layer was subjected to differential scanning calorimetry analysis. It is a DSC curve which shows the result of (DSC analysis).
  • the mirabegron-related substance relative to the total amount of mirabegron-related substance in the 0% crystalline maltose preparation after storing the oral pharmaceutical composition (bilayer tablet) prepared in Test Example 7 at 40 ° C. and 75% relative humidity for 2 weeks.
  • single agent means an embodiment of a preparation containing one kind of drug.
  • single preparation is also called “mixture” and means an embodiment of a preparation containing two or more kinds of drugs in the same preparation.
  • preparations having different functions relating to release characteristics are included in the same preparation, such as the release control section and the rapid release section in the present invention, also corresponds to a single preparation.
  • the “single preparation” for example, a two-layer tablet in which a release control part and an immediate release part are laminated, a multilayer tablet in which a plurality of quick release parts and release control parts are laminated, a release control part and an immediate release Multi-layer tablets such as a three-layer tablet with a drug-free layer added between them, a dry-coated tablet with a release control part in the inner core and an immediate release part in the outer layer, and a quick release to the core tablet of the release control part Examples thereof include a film-coated tablet having a free part film-coated.
  • Another embodiment includes a bilayer tablet.
  • the “release control part” means a part that controls the release of a drug contained in a single preparation.
  • the “rapid release part” means a part contained in a single preparation that releases drug from a pharmaceutical composition quickly (in the case of a substance that is easily soluble, almost coincides with elution). . Rapid release (elution) means that drug release is not controlled.
  • “to improve the stability of mirabegron or a pharmaceutically acceptable salt thereof” refers to preservation of a pharmaceutical composition for oral administration containing mirabegron or a pharmaceutically acceptable salt thereof. In other cases, it means “suppressing the production of a related substance of mirabegron or a pharmaceutically acceptable salt thereof during storage", and in another aspect, “change in the dissolution rate of mirabegron from the release control part" Means to suppress.
  • “suppressing the production of mirabegron or a pharmaceutically acceptable salt related substance thereof during storage” means that the amount of the related substance of the drug is the amount indicated in the guidelines on the impurities of the preparation. It means that the amount does not exceed. Specifically, based on the concept regarding related substances (impurities) in pharmaceutical preparations described in Pharmaceutical Examination No.
  • the related substances contained in mirabegron or its pharmaceutically acceptable salts are defined as an embodiment having a specific percentage or less.
  • a pharmaceutical composition for oral administration is abbreviated to 40 ° C. and 75% relative humidity (hereinafter referred to as% RH).
  • the sample is stored for one month under open conditions, and then measured by a high performance liquid chromatography method (hereinafter sometimes abbreviated as HPLC method).
  • HPLC method high performance liquid chromatography method
  • the percentage of the maximal analog of mirabegron or a pharmaceutically acceptable salt thereof in the pharmaceutical composition for oral administration is, for example, 0.5% or less, in some embodiments 0.3% or less, and in other embodiments 0. It is defined as 18% or less.
  • the maximum related substance of mirabegron or a pharmaceutically acceptable salt thereof is specifically determined by measuring the peak area of each related substance contained in the pharmaceutical composition for oral administration by the HPLC method. Is defined as the substance having the highest percentage of the salt and its related substances to the total peak area.
  • the total amount of mirabegron or a pharmaceutically acceptable salt thereof for example, after storing the pharmaceutical composition for oral administration for 1 month under 40 ° C. and 75% RH release condition, Measured by HPLC method. It is defined that the total amount of related substances of mirabegron or a pharmaceutically acceptable salt thereof in a pharmaceutical composition for oral administration is, for example, 1.5% or less, and in one embodiment, 1% or less.
  • the conditions of 2 months, 3 months, or 6 months under the same conditions can also be adopted. Moreover, it can select and set suitably from the conditions from 1 month to 24 months or 36 months on 25 degreeC and 60% RH open
  • the maximum related substance of solifenacin or a pharmaceutically acceptable salt thereof is specifically determined by measuring the peak area of each related substance contained in a pharmaceutical composition for oral administration by HPLC.
  • Solifenacin or a pharmaceutically acceptable salt thereof and related substances are defined as substances having the highest ratio to the total peak area.
  • a pharmaceutical composition for oral administration was stored for 1 month under 40 ° C. and 75% RH open conditions. Thereafter, it is measured by the HPLC method.
  • inhibiting the change in the dissolution rate of mirabegron from the release control unit during storage means to reduce the change in the dissolution rate of mirabegron from the release control unit, more specifically, It means to reduce the difference between the dissolution rate after storage and the dissolution rate before storage.
  • a pharmaceutical composition for oral administration is stored at 40 ° C.
  • the pharmaceutical composition for oral administration is stored at 40 ° C.
  • the change in elution rate after 1.5 hours (difference between the elution rate after storage and the elution rate before storage) when the elution test is carried out according to the acid buffer (900 mL) is 6% or less before and after storage. means. As another aspect, it means that the change in dissolution rate after 2.5 hours is 11% or less before and after storage. As another aspect, it means that the change in elution rate after 4.5 hours is 9% or less before and after storage.
  • the “crystalline saccharide” means a crystalline saccharide in a final preparation produced through a preparation process.
  • the term “crystal” saccharide means a saccharide having a crystallographic crystal structure.
  • the embodiment includes an amorphous saccharide together with a crystalline saccharide within a range that does not affect the stability of mirabegron or a pharmaceutically acceptable salt thereof.
  • the term “amorphous” saccharide means a saccharide that does not have a crystallographic structure (a saccharide having an amorphous structure).
  • the crystal state can be measured by, for example, a differential scanning calorimeter analysis (DSC analysis) method, a powder X-ray diffraction method, a solid-state NMR method, a near infrared spectroscopy (NIR) method, and the like.
  • DSC analysis differential scanning calorimeter analysis
  • NMR near infrared spectroscopy
  • DSC analysis differential scanning calorimeter analysis
  • Differential scanning calorimetry analysis is performed using, for example, an EXSTAR6000 series DSC6220 manufactured by Seiko Instruments Inc.
  • Approximately 5 mg of the sample is filled in a dedicated aluminum sample pan, and the measurement range is set to room temperature to 160 ° C under a nitrogen atmosphere (20 mL / min), and the sample and reference (empty aluminum sample are set at a heating rate of 10 ° C / min. Continuously measure and record the change in heat generated between Note that handling of devices including data processing follows the method and procedure instructed by each device.
  • a crystal maltose having an endothermic peak in the range of about 125 ° C. ⁇ 5 ° C. when measured under the above conditions is defined. The crystallinity of maltose is calculated from the peak area ratio with 20 mJ / mg as 100%.
  • crystallization detection methods other than the DSC analysis method, for example, solid NMR method or near infrared spectroscopy (NIR) method
  • solid NMR method for example, AVANCE 400 Bruker
  • NMR near infrared spectroscopy
  • MPA Bruker
  • Solifenacin or a pharmaceutically acceptable salt thereof used in the present invention can be easily obtained, for example, by the method described in Patent Document 5 or by production according thereto.
  • Solifenacin can form a pharmaceutically acceptable salt with an acid in addition to a free form that does not form a salt.
  • salts include acid addition salts with inorganic acids such as hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, nitric acid, phosphoric acid, formic acid, acetic acid, propionic acid, oxalic acid, malonic acid, succinic acid
  • acid addition salts with organic acids such as fumaric acid, maleic acid, lactic acid, malic acid, citric acid, tartaric acid, carbonic acid, picric acid, methanesulfonic acid, ethanesulfonic acid, and glutamic acid.
  • succinate can be mentioned.
  • Solifenacin or salts thereof pharmaceutically acceptable have selective antagonistic action against muscarine M 3 receptors are useful as therapeutic agents for overactive bladder.
  • solifenacin in administration of a single preparation is appropriately determined according to individual cases in consideration of symptoms, age of administration, sex and the like.
  • solifenacin succinate it is usually about 0.01 mg or more and 100 mg or less per day in the case of oral administration, and this is administered once a day or divided into 2 to 4 times.
  • the blending ratio of solifenacin or a pharmaceutically acceptable salt thereof is not particularly limited as long as it is a therapeutically or prophylactically effective amount. As such a blending ratio, for example, it is 0.5% by weight or more and 85% by weight or less with respect to the weight of the quick release part. As a further embodiment, it is 0.5 wt% or more and 10 wt% or less.
  • the amount of solifenacin or a pharmaceutically acceptable salt thereof is 0.01 mg or more and 100 mg or less in the whole preparation, and in another embodiment, 0.5 mg or more and 50 mg or less. 5 mg or more and 20 mg or less, yet another embodiment is 0.5 mg or more and 10 mg or less, and yet another embodiment is 2.5 mg, 5 mg or 10 mg.
  • the “rapid release part” in the present invention indicates the elution rate and / or maximum elution rate of solifenacin from the immediate release part as described below.
  • the “maximum dissolution rate” refers to, as one aspect, a dissolution test under certain conditions, and the dissolution rate when the drug dissolution rate from the pharmaceutical composition has leveled off. It means the dissolution rate after a certain period of time (for example, after 60 minutes).
  • the elution rate of solifenacin from the immediate-release part of the present invention is not particularly limited as long as it shows an in vivo utilization rate equivalent to that of the current formulation (single agent) of solifenacin.
  • Japanese Pharmacopoeia Dissolution Test Method 2 (Paddle Method, 50 rpm to 200 rpm)
  • Japanese Pharmacopoeia Dissolution Test Method 1 Japanese Pharmacopoeia Dissolution Test Method 1 (Rotating Basket Method, 50 rpm to 200 rpm)
  • US Pharmacopoeia Dissolution Test (Paddle Method)
  • US Pharmacopoeia When testing by dissolution test rotating basket method
  • the drug After 15 minutes, the drug elutes 85% or more, as another aspect, 90% or more elutes, (2) After 30 minutes Elution of 90% or more of the drug, 95% or more of the elution as another embodiment, (3) elution of 90% or more of the drug after 60 minutes, or 95% or more of the elution as another embodiment In yet another embodiment, it is specified that 97% or more is eluted.
  • Another aspect of the test method is the Japanese Pharmacopoeia dissolution test method 1 (rotating basket method, 100 rpm, test solution is water or USP pH 6.8 phosphate buffer, 900 mL).
  • the elution rate of solifenacin from the immediate release part is defined by combining one or more kinds of regulations from the provisions of (1), (2) and (3).
  • the maximum elution rate of solifenacin from the immediate-release part of the present invention is not particularly limited as long as it shows an in vivo use rate equivalent to that of the current formulation (single agent) of solifenacin.
  • Japanese Pharmacopoeia Dissolution Test Method 2 (Paddle Method, 50 rpm to 200 rpm)
  • Japanese Pharmacopoeia Dissolution Test Method 1 Japanese Pharmacopoeia Dissolution Test Method 1 (Rotating Basket Method, 50 rpm to 200 rpm)
  • US Pharmacopoeia Dissolution Test (Paddle Method)
  • US Pharmacopoeia US Pharmacopoeia
  • the test is performed by a dissolution test (rotating basket method) or the like, the drug dissolution rate after 60 minutes is specified.
  • the dissolution rate of the drug after 60 minutes when the test is performed by the Japanese Pharmacopoeia First Method (Rotating Basket Method, 100 rpm, test solution is water or USP pH 6.8 phosphate buffer, 900 mL) It is prescribed by.
  • the maximum elution rate in the rapid release part for example, the drug elution rate after 60 minutes is 90% or more, and in another aspect, the drug elution rate is defined as 92% or more.
  • the drug dissolution rate is 95% or more, and in another embodiment, the drug dissolution rate is defined as 97% or more.
  • Examples of pharmaceutical additives that improve the stability of mirabegron or a pharmaceutically acceptable salt thereof used in the immediate release part of the present invention include crystalline saccharides and / or water-soluble polymers.
  • Crystalline saccharide means a crystalline saccharide in the final preparation produced through the formulation process.
  • the formulation process includes grinding, mixing, granulation, molding, and film coating as described later, but even if crystalline saccharide is used as a raw material, it may be included in the final formulation as amorphous saccharide. .
  • the crystalline saccharide is not particularly limited as long as the crystalline saccharide is measured in the final preparation and improves the stability of mirabegron or a pharmaceutically acceptable salt thereof.
  • Specific examples include crystalline maltitol, crystalline erythritol, crystalline xylitol, crystalline maltose, crystalline lactose, crystalline sucrose, crystalline glucose, crystalline sorbitol, crystalline trehalose, crystalline lactitol, crystalline fructose, crystalline arabinose, and the like.
  • crystalline maltitol, crystalline erythritol, crystalline xylitol, etc. which are saccharides having strong crystallinity can be mentioned.
  • saccharides that crystallize by making it dry after humidification etc.
  • saccharides such as crystalline maltose, crystalline lactose, crystalline sucrose, crystalline glucose, crystalline sorbitol, crystalline trehalose, crystalline lactitol, crystalline fructose, etc.
  • Another embodiment includes crystalline maltose, crystalline glucose, crystalline fructose, crystalline arabinose and the like, which are crystalline reducing sugars.
  • crystal maltose is mentioned as another aspect.
  • the water-soluble polymer is not particularly limited as long as it improves the stability of mirabegron or a pharmaceutically acceptable salt thereof.
  • polyethylene glycol, hydroxypropyl cellulose, and polyvinyl pyrrolidone can be given as certain embodiments.
  • hydroxypropyl cellulose can be mentioned.
  • the water-soluble polymer is not particularly limited as long as it has a viscosity and molecular weight that can be used as a binder and can provide a single preparation in which the dissolution profile of solifenacin is not different from that of a single agent.
  • the viscosity of the water-soluble polymer for example, the viscosity of a 2% aqueous solution (20 ° C.) is 1 mPa ⁇ s or more and 20 mPa ⁇ s or less, and in one embodiment, the viscosity of a 2% aqueous solution (20 ° C.) is 2 mPa ⁇ s. It is 10 mPa ⁇ s or less.
  • the molecular weight of the water-soluble polymer is, for example, not less than 4000 and not more than 100,000.
  • polyethylene glycol examples include PEG 4000, PEG 6000, PEG 20000 (trade name, manufactured by NOF Corporation), and Polyglycol 8000PF (trade name, manufactured by Clariant).
  • hydroxypropyl cellulose examples include HPC-SSL (trade name, manufactured by Nippon Soda Co., Ltd.) (viscosity of 2% aqueous solution at 20 ° C .: 2.0-2.9 mPa ⁇ s), HPC-SL (trade name, Nippon Soda Co., Ltd.) (viscosity of 2% aqueous solution at 20 ° C .: 3.0-5.9 mPa ⁇ s), HPC-L (trade name, manufactured by Nippon Soda Co., Ltd.) (2% aqueous solution at 20 ° C. Viscosity: 6.0 to 10.0 mPa ⁇ s).
  • polyvinylpyrrolidone examples include PVP K30 (trade name, manufactured by BASF).
  • These pharmaceutical additives can be contained, for example, as excipients and / or binders in the immediate release part. These pharmaceutical additives can be used alone or in combination of two or more.
  • the blending ratio of the pharmaceutical additive for improving the stability of mirabegron or a pharmaceutically acceptable salt thereof contained in the immediate release part is, for example, 0.3% by weight or more and 99% by weight with respect to the weight of the immediate release part. It is 1 weight% or more and 99 weight% or less as another embodiment. Or, for example, 0.01 wt% or more and 99 wt% or less, 0.1 to 50 wt% or less as another embodiment, and 0.5 to 50 wt% as a further embodiment with respect to the total weight of the preparation. % Or less. In still another embodiment, it is 1% by weight to 50% by weight.
  • 1% by weight or more and 100% by weight or less, 3% by weight or more and 100% by weight or less, and 5% by weight as a further aspect with respect to the weight of mirabegron or a pharmaceutically acceptable salt thereof. It is 100 wt% or less, in another embodiment, 10 wt% or more and 100 wt% or less, and in still another embodiment, 20 wt% or more and 100 wt% or less.
  • the blending ratio is, for example, relative to the weight of the immediate-release part 50 wt% or more and 99 wt% or less, in another embodiment, 70 wt% or more and 95 wt% or less, and in another embodiment, 80 wt% or more and 95 wt% or less.
  • the blending ratio when a pharmaceutical additive that improves the stability of mirabegron or a pharmaceutically acceptable salt thereof contained in the immediate release part is used as a binder is, for example, relative to the weight of the immediate release part 1 wt% or more and 30 wt% or less, in another embodiment, 1 wt% or more and 20 wt% or less, and in another embodiment, 1 wt% or more and 15 wt% or less.
  • the pharmaceutical additive that improves the stability of mirabegron or a pharmaceutically acceptable salt thereof contained in the immediate release part is a crystalline saccharide
  • the blending ratio of the crystalline saccharide is mirabegron or a pharmaceutically acceptable salt thereof.
  • the proportion of crystalline saccharide is 5% by weight or more and 100% by weight or less, in one embodiment, 10% by weight or more and 100% by weight or less, and in another embodiment, 20% by weight or more and 100% by weight or less. It is 30 weight% or less and 100 weight% or less as a further aspect.
  • calcium stearate can be blended in the quick release part.
  • the calcium stearate contained in the quick release part in the present invention is not particularly limited as long as it conforms to the standards of Japanese Pharmacopoeia, US Pharmacopoeia or European Pharmacopoeia.
  • An example is Parteck (registered trademark) LUB CST (trade name, manufactured by MERCK).
  • the blending ratio of calcium stearate is, for example, from 0.1% by weight to 10% by weight with respect to the weight of the immediate release part, and as another aspect, from 0.5% by weight to 3.0% by weight. In another embodiment, it is 0.5 wt% or more and 2.0 wt% or less, and in another embodiment, it is 0.5 wt% or more and 1.5 wt% or less. Or it is 0.05 weight% or more and 6 weight% or less with respect to the weight of the whole preparation, and is 0.2 weight% or more and 1 weight% or less as another aspect.
  • Mirabegron or a pharmaceutically acceptable salt thereof used in the release control unit of the present invention can be easily obtained by, for example, the method described in Patent Document 2 or a method similar thereto.
  • Mirabegron can form pharmaceutically acceptable salts with acids in addition to the free form that does not form salts.
  • salts include acid addition salts with inorganic acids such as hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, nitric acid, phosphoric acid, formic acid, acetic acid, propionic acid, oxalic acid, malonic acid, succinic acid
  • acid addition salts with organic acids such as fumaric acid, maleic acid, lactic acid, malic acid, citric acid, tartaric acid, carbonic acid, picric acid, methanesulfonic acid, ethanesulfonic acid, and glutamic acid.
  • the free body which does not form a salt can be mentioned. These salts can be produced by conventional methods.
  • Mirabegron or a pharmaceutically acceptable salt thereof has a ⁇ 3 adrenergic receptor agonistic action and is useful as a therapeutic agent for overactive bladder.
  • the dosage of mirabegron or a pharmaceutically acceptable salt thereof in a single preparation (mixture) is appropriately determined according to individual cases in consideration of symptoms, age of the subject, sex, etc. In general, in the case of oral administration, it is about 0.01 mg or more and 100 mg or less per day for an adult, and this is administered once or divided into 2 to 4 times.
  • the blending ratio of mirabegron or a pharmaceutically acceptable salt thereof is, for example, 1% by weight or more and 70% by weight or less with respect to the weight of the controlled release part, and in another embodiment, 5% by weight or more and 70% by weight or less. As an aspect of this, it is 5 to 50 weight%.
  • the blending amount of mirabegron or a pharmaceutically acceptable salt thereof is 1 mg to 500 mg in the whole preparation, 10 mg to 200 mg as another aspect, and 25 mg or 50 mg as another aspect.
  • an appropriate test solution 900 mL for example, USP pH 6.8 phosphate buffer solution
  • the paddle rotation speed is 100 rotations.
  • Rotate the paddle using 900 mL of an appropriate test solution (eg USP pH 6.8 phosphate buffer solution or pH 6.8 Mc.Ilvain buffer solution) under the conditions of / min (rpm) or Japanese Pharmacopoeia Dissolution Test Method 2.
  • an appropriate test solution eg USP pH 6.8 phosphate buffer solution or pH 6.8 Mc.Ilvain buffer solution
  • the drug dissolution rate from the drug product was less than 85% 30 minutes after the start of the test, and the drug release was controlled to such an extent that the effect of food intake was reduced. It is a formulation. More specifically, in a dissolution test conducted using 900 mL of USP pH 6.8 phosphate buffer solution under the condition of a paddle rotation speed of 200 rpm, from the preparation 30 minutes after the start of the test or 1.5 hours after the start of the test. The drug dissolution rate is less than 85%.
  • a preparation comprising a combination of a drug (mirabegron or a pharmaceutically acceptable salt thereof) and a polymer substance that forms a hydrogel, or a drug (mirabegron or a pharmaceutically acceptable salt thereof) An acceptable salt), an additive (hydrophilic base) for allowing water to penetrate into the preparation, and a polymer substance that forms a hydrogel.
  • the drug (mirabegron or The pharmaceutically acceptable salt), an additive (hydrophilic base) for allowing water to enter the inside of the preparation, and a polymer substance that forms a hydrogel.
  • the polymer substance forming the hydrogel used in the present invention is not particularly limited as long as it can control the drug release rate to such an extent that the blood concentration profile of the drug is not affected by the presence or absence of food intake.
  • the molecular weight of the polymer material forming the hydrogel is, for example, 100,000 or more, 100,000 to 8 million as another embodiment, 100,000 to 5 million as another embodiment, and 100,000 as another embodiment. More than 2 million.
  • the viscosity of the polymer material forming the hydrogel is, for example, a 5% aqueous solution (25 ° C.) having a viscosity of 12 mPa ⁇ s or higher, and in another aspect, a 5% aqueous solution (25 ° C.) having a viscosity of 12 mPa ⁇ s or higher.
  • Aqueous solution (25 ° C.) has a viscosity of 40,000 mPa ⁇ s or less
  • a 2% aqueous solution (25 ° C.) has a viscosity of 400 mPa ⁇ s or more and a 1% aqueous solution (25 ° C.) has a viscosity of 7500 mPa ⁇ s or less.
  • the viscosity of a 2% aqueous solution (25 ° C.) is 400 mPa ⁇ s or more and the viscosity of a 1% aqueous solution (25 ° C.) is 5500 mPa ⁇ s or less.
  • polymer substance forming the hydrogel used in the present invention examples include polyethylene oxide, hypromellose, hydroxypropylcellulose, methylcellulose, sodium carboxymethylcellulose, hydroxyethylcellulose, and carboxyvinyl polymer.
  • Other embodiments include polyethylene oxide, hypromellose, and hydroxypropyl cellulose.
  • Another embodiment includes polyethylene oxide.
  • Examples of the polyethylene oxide include, for example, trade name Polyox WSR-308 [average molecular weight: 8 million, viscosity: 10,000-15000 mPa ⁇ s (1% aqueous solution 25 ° C.)], Polyox WSR- 303 [average molecular weight: 7 million, viscosity: 7500-10000 mPa ⁇ s (1% aqueous solution 25 ° C.)], Polyox WSR Coagulant [average molecular weight: 5 million, viscosity: 5500-7500 mPa ⁇ s (1% aqueous solution 25 ° C.)], Polyox WSR-301 [average molecular weight: 4 million, viscosity: 1650-5500 mPa ⁇ s (1% aqueous solution 25 ° C.)], Polyox WSR-N-60K [average molecular weight: 2 million, viscosity: 2000-4000 mPa ⁇ s
  • HPMC hypromellose
  • examples of hypromellose include, for example, trade name Metroze 90SH50000 [viscosity of 2% aqueous solution at 20 ° C .: 2900-3900 mPa ⁇ s], Metrose SB-4 (trade name, Shin-Etsu Chemical Co., Ltd.) Co., Ltd.) (viscosity of 2% aqueous solution at 20 ° C .: about 4 mPa ⁇ s), TC-5RW (trade name, manufactured by Shin-Etsu Chemical Co., Ltd.) (viscosity of 2% aqueous solution at 20 ° C .: about 6 mPa ⁇ s) TC-5S (trade name, manufactured by Shin-Etsu Chemical Co., Ltd.) (viscosity of 2% aqueous solution at 20 ° C .: about 15 mPa ⁇ s), TC-5R (trade name, manufactured by Shin-Etsu Chemical
  • TC-5M (trade name, manufactured by Shin-Etsu Chemical Co., Ltd.) (viscosity of 2% aqueous solution at 20 ° C .: about 4.5 mPa ⁇ s)
  • TC-5 (Trade name, manufactured by Shin-Etsu Chemical Co., Ltd.) (viscosity of 2% aqueous solution at 20 ° C .: about 3 mPa ⁇ s)
  • Metrose 60SH-50 (trade name, manufactured by Shin-Etsu Chemical Co., Ltd.) (2% at 20 ° C.
  • Viscosity of aqueous solution about 50 mPa ⁇ s
  • Metroze 65SH-50 trade name, manufactured by Shin-Etsu Chemical Co., Ltd.
  • Metroze 90SH-100 trade name, (Manufactured by Shin-Etsu Chemical Co., Ltd.) (viscosity of 2% aqueous solution at 20 ° C .: about 100 mPa ⁇ s
  • Metrows 90SH-100SR trade name, manufactured by Shin-Etsu Chemical Co., Ltd.
  • Metroze 65 SH-400 trade name, manufactured by Shin-Etsu Chemical Co., Ltd.
  • HPC hydroxypropylcellulose
  • HPC-SSL trade name, manufactured by Nippon Soda Co., Ltd.
  • HPC-SL (trade name, manufactured by Nippon Soda Co., Ltd.) (viscosity of 2% aqueous solution at 20 ° C .: 3.0-5.9 mPa ⁇ s)
  • HPC-L (trade name, Nippon Soda Co., Ltd.) (Viscosity of 2% aqueous solution at 20 ° C .: 6.0-10.0 mPa ⁇ s)
  • HPC-M (trade name, manufactured by Nippon Soda Co., Ltd.) (Viscosity of 2% aqueous solution at 20 ° C .: 150- 400 mPa ⁇ s
  • HPC-H (trade name, manufactured by Nippon Soda Co., Ltd.) (viscosity of 2% aqueous solution at 20 ° C .: 1000-4000 mPa ⁇ s).
  • methylcellulose examples include Metroze SM15 (trade name, manufactured by Shin-Etsu Chemical Co., Ltd.) (viscosity of 2% aqueous solution at 20 ° C .: about 15 mPa ⁇ s), Metrouse SM25 ( Trade name, manufactured by Shin-Etsu Chemical Co., Ltd.) (viscosity of 2% aqueous solution at 20 ° C .: about 25 mPa ⁇ s), Metrows SM100 (trade name, manufactured by Shin-Etsu Chemical Co., Ltd.) (viscosity of 2% aqueous solution at 20 ° C.
  • Metrows SM400 (trade name, manufactured by Shin-Etsu Chemical Co., Ltd.) (viscosity of 2% aqueous solution at 20 ° C .: about 400 mPa ⁇ s)
  • Metrows SM 1500 (trade name, manufactured by Shin-Etsu Chemical Co., Ltd.) (Viscosity of 2% aqueous solution at 20 ° C .: about 1500 mPa ⁇ s)
  • Metrows SM4000 (trade name, manufactured by Shin-Etsu Chemical Co., Ltd.) (20 2% viscosity of aqueous solution at: about 4000 mPa ⁇ s) and the like.
  • CMCNa sodium carboxymethyl cellulose
  • examples of sodium carboxymethyl cellulose include, for example, trade name Sunrose F-30MC [viscosity: 250-350 mPa ⁇ s (1% aqueous solution 25 ° C.)], Sunrose F-150MC [average Molecular weight: 200,000, viscosity: 1200-1800 mPa ⁇ s (1% aqueous solution 25 ° C)], Sunrose F-600MC [viscosity: 6000-8000 mPa ⁇ s (1% aqueous solution 25 ° C)], Sunrose F-1000MC [average Molecular weight: 420,000, Viscosity: 8000-12000 mPa ⁇ s (1% aqueous solution 25 ° C.)], Sunrose F-1400MC [Viscosity: 12000-15000 mPa ⁇ s (1% aqueous solution 25 ° C.)], Sunrose F-300MC [Average Molecular weight: 300,000, Viscosity: 300
  • HEC hydroxyethyl cellulose
  • HEC Daicel SE850 average molecular weight: 1,480,000, viscosity: 2400-3000 mPa ⁇ s (1% aqueous solution 25 ° C.)
  • HEC Daicel SE900 Average molecular weight: 1,560,000, viscosity: 4000-5000 mPa ⁇ s (1% aqueous solution 25 ° C.)] (manufactured by Daicel Chemical Industries).
  • carboxyvinyl polymer examples include Carbopol 940 (average molecular weight of about 2.5 million, manufactured by BF Goodrich Chemical).
  • the mixing ratio of the polymer substance that forms the hydrogel is not particularly limited as long as the blood concentration profile of the drug is not affected by the presence or absence of food intake, but for example, relative to the weight of the release control unit 1% by weight or more and 70% by weight or less, in another aspect, 3% by weight or more and 70% by weight or less, and in another aspect, 5% by weight or more and 70% by weight or less, and in another aspect, 10% by weight or more and 60% by weight or less. It is 10 wt% or more and 40 wt% or less.
  • 1% by weight to 45% by weight relative to the total weight of the preparation in another aspect, 2% by weight or more and 45% by weight or less, and in another aspect, 3% by weight or more and 45% by weight or less, As an aspect, it is 5 to 35 weight%, and as another aspect, it is 5 to 25 weight%.
  • the blending ratio of the polymer substance forming the hydrogel is 0.1% by weight or more and 1000% by weight or less with respect to the weight of the drug, as another embodiment, 1% by weight or more and 500% by weight or less, and as another embodiment 5 % By weight or more and 300% by weight or less.
  • the amount of water required for dissolving 1 g of the hydrophilic base is 20 ⁇ 5 ° C. 10 mL or less, another embodiment is 6 mL or less, another embodiment is 5 mL or less, and yet another embodiment is 4 mL or less.
  • hydrophilic base examples include polyethylene glycol [PEG; for example, trade names PEG400, PEG1500, PEG4000, PEG6000, PEG20000 (manufactured by NOF Corporation), Polyglycol 8000PF (manufactured by Clariant)], polyvinylpyrrolidone [PVP; , Trade name PVP K30 (manufactured by BASF)], sugar alcohols such as D-mannitol, D-sorbitol, xylitol; lactose, sucrose, anhydrous maltose, D-fructose, dextran (eg, dextran 40), Sugars such as glucose; polyoxyethylene hydrogenated castor oil [HCO; for example, Cremophor RH40 (manufactured by BASF), HCO-40, HCO-60 (manufactured by Nikko Chemicals)], polyoxyethylene polyoxy Surfactants such as propylene glycol [eg Pluronic F68 (Asa), Plur
  • Another embodiment includes PEG, PVP, D-mannitol, lactose, sucrose, sodium chloride, polyoxyethylene polyoxypropylene glycol.
  • Yet another embodiment includes PEG.
  • hydrophilic bases can be used alone or in combination of two or more.
  • the blending ratio of the hydrophilic base is not particularly limited as long as the drug release can be controlled to such an extent that it is not affected by food intake. For example, it is 5% by weight or more and 75% by weight or less with respect to the weight of the release control part. Or it is 3 weight% or more and 44 weight% or less with respect to the weight of the whole preparation, as another aspect, it is 3 weight% or more and 40 weight% or less, and as another aspect, it is 12 weight% or more and 35 weight% or less.
  • an antioxidant may be blended.
  • the antioxidant is not particularly limited as long as the influence of elution behavior can be avoided.
  • dibutylhydroxytoluene (BHT), propyl gallate (PG), butylhydroxyanisole (BHA), ascorbic acid, sodium ascorbate, erythorbic acid, sodium nitrite, sodium bisulfite, sodium pyrosulfite, citric acid, edetic acid Sodium is mentioned, BHT, PG, sodium ascorbate is mentioned as another aspect, and BHT is mentioned as another aspect.
  • antioxidants can be appropriately added in an appropriate amount, alone or in combination of two or more.
  • the blending ratio of the antioxidant is, for example, 0.025 wt% or more and 0.25 wt% or less with respect to the weight of the release control unit. Or as another aspect, it is 0.015 weight% or more and 0.15 weight% or less with respect to the weight of the whole formulation.
  • the stabilizer in the present invention may contain a stabilizer.
  • the stabilizer is not particularly limited as long as it does not change the drug release characteristics over time when polyethylene oxide is used as the polymer substance forming the hydrogel.
  • yellow iron sesquioxide, red iron sesquioxide, black iron oxide and the like can be mentioned.
  • the stabilizers can be appropriately added in an appropriate amount, alone or in combination.
  • the blending ratio of the stabilizer is 0.05% by weight or more and 1% by weight or less with respect to the weight of the release control part. Or as another aspect, it is 0.03 weight% or more and 0.6 weight% or less with respect to the weight of the whole formulation.
  • various pharmaceutical additives are appropriately used and formulated as long as the desired effect of the invention is achieved.
  • a pharmaceutical additive is not particularly limited as long as it is pharmaceutically acceptable and pharmacologically acceptable.
  • an excipient, a binder, a disintegrant, a sour agent, a foaming agent, a sweetener, a fragrance, a colorant, a buffer, an antioxidant, a surfactant and the like are used.
  • excipients include starch, pregelatinized starch, dextrin, crystalline cellulose, low-substituted hydroxypropylcellulose, sodium carboxymethylcellulose, gum arabic, dextrin, pullulan, light anhydrous silicic acid, synthetic aluminum silicate, and metasilicate aluminum.
  • examples include magnesium acid.
  • the binder include gum arabic, hypromellose, hydroxyethyl cellulose and the like.
  • Examples of the disintegrant include corn starch, potato starch, carmellose calcium, carmellose sodium, and low-substituted hydroxypropylcellulose.
  • Examples of the sour agent include citric acid, tartaric acid, malic acid and the like.
  • Examples of the foaming agent include sodium bicarbonate.
  • Examples of the sweetener include saccharin sodium, glycyrrhizic acid, aspartame, stevia, thaumatin and the like.
  • Examples of the fragrances include lemon, lemon lime, orange, menthol and the like.
  • Examples of the colorant include food yellow No. 4, No. 5, food red No. 3, No. 102, food blue No. 3, and the like.
  • Buffers include citric acid, succinic acid, fumaric acid, tartaric acid, ascorbic acid or salts thereof, glutamic acid, glutamine, glycine, aspartic acid, alanine, arginine or salts thereof, magnesium oxide, zinc oxide, magnesium hydroxide, phosphoric acid , Boric acid or a salt thereof.
  • Examples of the surfactant include polysorbate 80, sodium lauryl sulfate, polyoxyethylene hydrogenated castor oil, and the like.
  • These pharmaceutical additives can be appropriately added in an appropriate amount by combining one or more kinds.
  • any pharmaceutical additive is used in an amount within the range in which the desired effect of the present invention is achieved.
  • composition (formulation) for oral administration of the present invention a single preparation (mixture) produced by a method known per se, for example, a layer containing mirabegron or a pharmaceutically acceptable salt thereof and solifenacin or a combination thereof And a pharmaceutical composition for oral administration comprising a layer containing a pharmaceutically acceptable salt.
  • a bilayer tablet in which a layer containing mirabegron or a pharmaceutically acceptable salt thereof and a layer containing solifenacin or a pharmaceutically acceptable salt thereof are laminated, mirabegron or a pharmaceutically acceptable salt thereof
  • a multi-layered tablet comprising a plurality of layers containing a salt that is allowed to be adsorbed and a layer containing solifenacin or a pharmaceutically acceptable salt thereof, a layer containing mirabegron or a pharmaceutically acceptable salt thereof, and solifenacin or a combination thereof
  • a multilayer tablet such as a three-layer tablet in which a layer not containing a drug is added between a layer containing a pharmaceutically acceptable salt and a release control unit containing mirabegron or a pharmaceutically acceptable salt thereof in the inner core And having a rapid release part containing solifenacin or a pharmaceutically acceptable salt thereof in the outer layer, or solifenacin or a core tablet of a controlled release part containing mirabegron or a pharmaceutically
  • a pharmaceutically acceptable coating the immediate release portion containing salts were film-coated tablets, and the like.
  • Another embodiment includes a bilayer tablet in which a layer containing mirabegron or a pharmaceutically acceptable salt thereof and a layer containing solifenacin or a pharmaceutically acceptable salt thereof are laminated.
  • the layer containing mirabegron or a pharmaceutically acceptable salt thereof is selected from the group consisting of a polymer substance forming a hydrogel, a hydrophilic base, an antioxidant, a stabilizer and a pharmaceutical additive.
  • a seed or two or more substances may be contained.
  • the above-mentioned substance can be used, respectively.
  • the layer containing solifenacin or a pharmaceutically acceptable salt thereof may contain one or more substances selected from the group consisting of excipients, binders, calcium stearate and pharmaceutical additives.
  • the above-mentioned substance can be used, respectively.
  • the pharmaceutical composition for oral administration of the present invention can be produced by appropriately combining methods known per se.
  • Pulverization / mixing step The pulverization step is not particularly limited as long as it is a method that can pharmaceutically pulverize drugs and appropriate pharmaceutical additives.
  • the pulverizer include a hammer mill, a ball mill, a jet pulverizer, and a colloid mill.
  • the grinding conditions are not particularly limited as long as they are appropriately selected.
  • the mixing step of each component continuous with the pulverization is not particularly limited to any device or means as long as it is a method that can generally uniformly mix each component pharmaceutically.
  • the apparatus and means of the step are no particular limitations on the apparatus and means of the step as long as it is a method capable of granulating a polymer substance or the like that forms a hydrogel.
  • the granulation method and apparatus include high-speed stirring granulation method, pulverization (pulverization) granulation method, fluidized bed granulation method, extrusion granulation method, rolling granulation method, spray granulation method, or those granulation methods
  • Examples include an apparatus used by the method.
  • Another aspect is a fluidized bed granulation method / apparatus, and another aspect is a rolling fluidized bed granulation method / apparatus. It can also be dried after granulation.
  • the drying method is not particularly limited as long as it is a method that can be usually pharmaceutically dried.
  • Rapid release part granulation step
  • the apparatus and means of the step there are no particular limitations on the apparatus and means of the step as long as it is a method capable of granulating drugs and the like.
  • a production method and apparatus for example, fluidized bed granulation method, melt granulation method, high speed stirring granulation method, crushing (pulverization) granulation method, extrusion granulation method, rolling granulation method, spray granulation method, Examples thereof include dry granulation methods and apparatuses used by these methods.
  • Another embodiment is a fluidized bed granulation method / apparatus.
  • the binder used in the wet granulation method one kind or two or more kinds can be used in appropriate combination.
  • the spray granulation method it can be dried after granulation.
  • the drying method is not particularly limited as long as it is a pharmaceutically drying method.
  • water is used as a binder solution for solifenacin or a pharmaceutically acceptable salt thereof, or for a mixture of solifenacin or a pharmaceutically acceptable salt thereof and a pharmaceutical additive.
  • all or part of the saccharide may exist in an amorphous state after drying.
  • the saccharide in the amorphous state in the preparation is crystallized by a crystallization step of saccharide such as humidification drying described later.
  • the crystalline saccharide When the crystalline saccharide is dissolved in water and the solution is sprayed as a binder solution, the crystalline saccharide is seeded by adding solifenacin or a pharmaceutically acceptable salt thereof and the crystalline saccharide. As a result, crystallization of saccharides in an amorphous state can be promoted.
  • the product temperature of the granulated product during granulation is not particularly limited.
  • the product temperature of the granulated product during granulation is not particularly limited as long as it is a product temperature at which sugars crystallize. Specifically, for example, it is 30 ° C. or lower, as one embodiment, 20 ° C. or higher and 30 ° C. or lower, and as another embodiment, 25 ° C. or higher and 30 ° C. or lower. As the product temperature is lower, the saccharide is more easily crystallized, and therefore the crystallization of the saccharide in the granulated product can be adjusted by adjusting the temperature.
  • Molding step There are no particular limitations on the device and means of the step as long as it is a method for molding the pharmaceutical composition for oral administration of the present invention.
  • a method of directly compressing and molding a tablet after mixing a drug and appropriate pharmaceutical additives without granulation / drying process, a method of granulating and mixing a lubricant and then compressing and manufacturing a tablet A method of stacking a release control part and a quick release part to make a two-layer tablet, a method of stacking a plurality of release control parts and a quick release part to make a multilayer tablet, and between a release control part and a quick release part
  • a method for producing a multi-layered tablet having a drug-free layer added thereto, a method for producing a dry-coated tablet having a release control part in the inner core and an immediate release part in the outer layer As another embodiment, a method for producing a bilayer tablet can be mentioned.
  • Examples of the tableting device include a rotary stacked tableting machine and an oil press.
  • the tableting conditions such as tableting pressure are not particularly limited as long as the tableting pressure can produce a bilayer tablet and / or a multilayer tablet.
  • the first-layer granulated product and the second-layer granulated product are laminated and compressed at about 2 to about 20 kN.
  • the first-layer granulated product is about 0. It is prepared by compressing at 1 to about 10 kN, then laminating the second granulation and compressing at about 2 to about 20 kN.
  • the tableting pressure can be appropriately adjusted and compressed.
  • the hardness of the tableted product is not particularly limited as long as it does not break during the manufacturing process or the distribution process. An example is 40 to 200N.
  • the method is not particularly limited as long as it is usually a pharmaceutically coating method. Examples thereof include pan coating and dip coating.
  • the film coating agent can be appropriately added in an appropriate amount by combining one kind or two or more kinds.
  • the coating rate is not particularly limited as long as it is a rate for forming a film. For example, it is 1 to 10% by weight relative to the weight of the whole preparation.
  • a spray solution in which the components of the rapid release part are dissolved and / or dispersed in a solvent such as water is used. Can be produced by spraying.
  • a film coating rate will not be restrict
  • the method is not particularly limited as long as it can be usually pharmaceutically dried.
  • the drying conditions are not particularly limited as long as they are appropriately set in consideration of, for example, the stability of the preparation.
  • the initial moisture value after film coating is preferably 0.1 to 2% in consideration of stability, for example.
  • Saccharide crystallization step for example, when the saccharide remains in the granulated product in an amorphous state in the (3) quick release part: granulation step, etc., solifenacin or its
  • the apparatus and means as long as they can crystallize the saccharide in the layer containing a pharmaceutically acceptable salt.
  • a method of humidifying and drying the obtained granulated product, tablet or the like can be mentioned.
  • “humidification” is determined by the apparent critical relative humidity of the mixture containing sugars, but usually humidifies above the critical relative humidity of the mixture.
  • the humidity is 30 to 100% RH, and in some embodiments, 50 to 90% RH.
  • the temperature at this time is 15 to 50 ° C. in one embodiment, and 20 to 40 ° C. in another embodiment.
  • the humidification time is, for example, 1 to 36 hours, and in one embodiment, 12 to 24 hours.
  • Drying is not particularly limited as long as it is a step of removing moisture absorbed by humidification. Such “drying” is, for example, 1% RH to 40% RH as humidity, and as one embodiment, 20 to 40% RH.
  • the temperature at this time is 10 to 100 ° C. in one embodiment, 20 to 60 ° C. in another embodiment, and 25 to 40 ° C. in another embodiment.
  • the drying time is 0.5 to 5 hours in one embodiment, and 1 to 3 hours in another embodiment.
  • a humidification dryer (a constant temperature and humidity machine) manufactured by Espec Corp.
  • the obtained granules, tablets, etc. are put into a humidifying dryer (constant temperature and humidity controller), humidified at 20 to 40 ° C. and 50 to 90% RH for 12 to 24 hours, and then 25 to 40 ° C., 20 to 20 ° C.
  • a humidifying dryer constant temperature and humidity controller
  • the obtained granules, tablets, etc. are put into a humidifying dryer (constant temperature and humidity controller), humidified at 20 to 40 ° C. and 50 to 90% RH for 12 to 24 hours, and then 25 to 40 ° C., 20 to 20 ° C.
  • a humidifying dryer constant temperature and humidity controller
  • the pharmaceutical composition for oral administration of the present invention is used, for example, as a pharmaceutical composition for treating urgency, frequent urination and / or urinary incontinence associated with overactive bladder.
  • the method for producing the pharmaceutical composition for oral administration of the present invention includes a method for producing the pharmaceutical composition by appropriately combining methods known per se in addition to the method described above.
  • the present invention includes a method for stabilizing mirabegron or a pharmaceutically acceptable salt thereof with crystalline saccharide and / or water-soluble polymer.
  • crystalline saccharide “water-soluble polymer”, “mirabegron or a pharmaceutically acceptable salt thereof” used in the stabilization method of the present invention, the description in the pharmaceutical composition for oral administration of the present invention is not changed. Can be applied.
  • oral administration comprising a controlled release part containing mirabegron or a pharmaceutically acceptable salt thereof and an immediate release part containing solifenacin or a pharmaceutically acceptable salt thereof.
  • the stability of mirabegron or a pharmaceutically acceptable salt thereof can be improved by blending a crystalline saccharide and / or a water-soluble polymer with the immediate-release part.
  • the said description in the pharmaceutical composition for oral administration of this invention and its manufacturing method is applicable as it is.
  • the present invention comprises (1) a controlled release part containing mirabegron or a pharmaceutically acceptable salt thereof, and (2) an immediate release part containing solifenacin or a pharmaceutically acceptable salt thereof.
  • a pharmaceutical composition for oral administration includes the use of crystalline saccharides and / or water-soluble polymers for a stable pharmaceutical composition for oral administration.
  • crystalline saccharide”, “water-soluble polymer”, “mirabegron or a pharmaceutically acceptable salt thereof” used in the present invention, the description in the pharmaceutical composition for oral administration of the present invention is applied as it is. be able to.
  • a controlled release part containing mirabegron or a pharmaceutically acceptable salt thereof, and an immediate release part containing solifenacin or a pharmaceutically acceptable salt thereof In providing a pharmaceutical composition for oral administration comprising, the stability of mirabegron or a pharmaceutically acceptable salt thereof can be improved by blending in the immediate release part.
  • a compounding method, the said description in the pharmaceutical composition for oral administration of this invention and its manufacturing method is applicable as it is.
  • Example 1 Preparation of Release Control Part Mixed Powder 24 kg of mirabegron was replaced with 33.6 kg of polyethylene oxide (POLYOX (registered trademark) N-60K, manufactured by Dow, hereinafter the same), polyethylene glycol 8000 (produced by Polyglycol 8000 PF, manufactured by Clariant, the same applies hereinafter) 57 .4 kg, and hydroxypropylcellulose (HPC-SL, manufactured by Nippon Soda Co., Ltd., the same shall apply hereinafter) 3.6 kg together with a screen mill (Comil, manufactured by QUADRO), and then the pulverized powder is fluidized bed granulator ( (GPCG-120, manufactured by Glatt) and granulated by spraying water.
  • POLYOX polyethylene oxide
  • polyethylene glycol 8000 produced by Polyglycol 8000 PF, manufactured by Clariant, the same applies hereinafter
  • HPC-SL hydroxypropylcellulose
  • Example 2 (1) Preparation of Release Control Part Mixed Powder A release control part mixed powder was obtained under the same formulation and production conditions as described in Example 1.
  • Example 3 (1) Preparation of Release Control Part Mixed Powder A release control part mixed powder was obtained according to the formulation described in Table 2 under the same production conditions as described in Example 1.
  • DSC Measurement After exfoliating only the immediate release part (solifenacin succinate layer) of the pharmaceutical composition for oral administration (bilayer tablet) of Example 1 and Reference Example 1, the solifenacin succinate layer was removed with a pestle mortar. Crushed. Differential scanning calorimetry analysis (DSC analysis) was performed using an EXSTAR6000 series DSC6220 manufactured by Seiko Instruments Inc. Approximately 5 mg of the sample is filled in a dedicated aluminum sample pan, and the measurement range is set to room temperature to 160 ° C under a nitrogen atmosphere (20 mL / min), and the sample and reference (empty aluminum sample are set at a heating rate of 10 ° C / min.
  • Example 2 ⁇ Test Example 2> Related Substances
  • the pharmaceutical compositions for oral administration (double-layer tablets) of Example 1, Example 2, Reference Example 1, Example 3, and Comparative Example 3 were put in an aluminum pouch and opened, 40 It was stored for one month under open conditions at 75 ° C. and 75% relative humidity. Related substances before and after storage were measured by HPLC. Tables 3 and 4 show the results of measurement of related substances of mirabegron, and Table 5 shows the results of measurement of related substances of solifenacin succinate.
  • the pharmaceutical composition for oral administration of Example 1 and Example 2 (bilayer tablet) containing crystalline maltose is more than the pharmaceutical composition for oral administration (bilayer tablet) of Reference Example 1 containing amorphous maltose, In addition, the percentage of related substances decreased.
  • Reference Example 1 (bilayer tablet) containing amorphous maltose
  • the pharmaceutical composition for oral administration of Reference Example 1 (bilayer tablet) containing amorphous maltose can also be provided to the medical site by applying moisture-proof packaging or the like.
  • the percentage of the related substance of Example 3 manufactured on a large scale, or Comparative Example 3 and the percentage of the maximum related substance are higher than those of Example 1 or Reference Example 1 manufactured with an oil press tableting machine. It is appropriate to evaluate examples and comparative examples produced under the same scale.
  • the related substances of mirabegron were measured under the following conditions.
  • As an HPLC column XBridge C18, particle size 3.5 ⁇ m, 4.6 mm (inner diameter) ⁇ 15 cm (manufactured by Waters) or an equivalent thereof was used and maintained at 40 ° C.
  • As mobile phase A 50 mmol / L phosphate buffer (pH 7.2) was used, and as mobile phase B, acetonitrile was used.
  • the sample solution used was diluted with methanol and 30% acetonitrile so that the concentration of the compound was 500 ⁇ g / mL.
  • solifenacin succinate was performed under the following conditions by peeling only the immediate-release part (solifenacin succinate layer) from the obtained bilayer tablet.
  • As an HPLC column XBridge C18, particle size 3.5 ⁇ m, 4.6 mm (inner diameter) ⁇ 15 cm (manufactured by Waters) or an equivalent thereof was used and maintained at 40 ° C.
  • As mobile phase A 50 mmol / L phosphate buffer (pH 7.2) was used, and as mobile phase B, acetonitrile was used.
  • the sample solution used was diluted with methanol and 30% acetonitrile so that the concentration of the compound was 250 ⁇ g / mL.
  • the flow rate was adjusted so that the retention time of solifenacin succinate was about 29 minutes, and a related substance was measured with an ultraviolet absorptiometer (wavelength: 210 nm), solifenacin succinate And the percentage of the peak area of the related substance as a percentage of the total peak area of the related substance.
  • Example 3 Mirabegron Dissolution Test
  • the pharmaceutical composition for oral administration (double-layer tablet) of Example 1 and Reference Example 1 was placed in an aluminum pouch and left open at 40 ° C. and a relative humidity of 75%. Saved months.
  • a dissolution test was performed according to the Japanese Pharmacopoeia dissolution test method 2 (paddle method, 200 rpm).
  • the test solution was 900 mL of USP pH 6.8 phosphate buffer, and the elution rate of mirabegron after 1.5 hours, 2.5 hours, and 4.5 hours after the start of the test was measured by ultraviolet spectroscopy (UV method (measurement wavelength: 247 nm / 450 nm)).
  • UV method ultraviolet spectroscopy
  • the difference between the dissolution rate of mirabegron after storage and the dissolution rate of mirabegron before storage at each time point before and after storage was calculated.
  • Table 8 In the pharmaceutical composition for oral administration of Example 1 (bilayer tablet) containing crystalline maltose, the change in dissolution rate is more than that of the pharmaceutical composition for oral administration of Reference Example 1 (bilayer tablet) containing amorphous maltose. It was even smaller.
  • the pharmaceutical composition for oral administration of Reference Example 1 (bilayer tablet) containing amorphous maltose can also be provided to the medical site by applying moisture-proof packaging or the like.
  • the dissolution rate and maximum dissolution rate of solifenacin in the pharmaceutical composition for oral administration of Example 1 and Reference Example 1 are the pharmaceutical compositions for oral administration of Comparative Example 1 and Comparative Example 2 (bilayer tablet). It was a high value compared with.
  • an immediate release part containing amorphous maltose and crystalline maltose in a specific ratio Prepared and evaluated the stability of mirabegron contained in other layers.
  • Amorphous maltose obtained by heat treatment at 150 ° C. for 30 minutes is weighed with crystalline maltose so that the total amount of maltose is 334 mg, and further mixed with solifenacin succinate 50 mg, mannitol 2916 mg, and calcium stearate 34 mg.
  • solifenacin succinate 50 mg, mannitol 2916 mg, and calcium stearate 34 mg A mixed powder was obtained.
  • the release control part mixed powder was obtained under the same formulation and production conditions as described in Reference Example 2. Tableting was performed under the same conditions as described in Example 1 to obtain a pharmaceutical composition for oral administration (bilayer tablet) containing 25 mg of mirabegron and 2.5 mg of solifenacin succinate. Put the obtained pharmaceutical composition for oral administration (double-layer tablet) in an aluminum pouch and store it for 2 weeks or 40 months under open conditions at 40 ° C and 75% relative humidity, and then measure the total amount of mirabegron related substances. It was measured.
  • FIG. 3 show the relationship between the ratio of the total amount of mirabegron-related substances to the total amount of mirabegron-related substances in the preparation with 0% crystalline maltose content after storage and the content of crystalline maltose in the maltose contained in the immediate-release part. From FIG. 2, the addition of 5% or more of crystalline maltose to the rapid release part could suppress the increase in the maximum related substance of mirabegron and the total amount of related substances.
  • the present invention relates to a pharmaceutical composition for oral administration comprising a controlled release part containing mirabegron or a pharmaceutically acceptable salt thereof and an immediate release part containing solifenacin or a pharmaceutically acceptable salt thereof.
  • a pharmaceutical composition for oral administration of the present invention it can be used as a preparation technique for providing a single preparation that suppresses the generation of related substances during storage of each drug and the change in the dissolution rate of mirabegron during storage.
  • this invention was demonstrated along the specific aspect, the deformation

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne une préparation pharmaceutique unique composée d'une partie à libération contrôlée comprenant un mirabegron ou un sel de celui-ci pharmaceutiquement acceptable et d'une partie à libération rapide comprenant de la solifénacine ou un sel de celle-ci pharmaceutiquement acceptable . La production d'analogues de chaque médicament pendant le stockage est commandée pour la préparation pharmaceutique unique, et des changements dans la vitesse d'élution du mirabegron pendant le stockage sont commandés pour la préparation pharmaceutique unique de telle sorte que la composition pharmaceutique unique peut être utilisée dans un milieu clinique. La composition pharmaceutique pour administration orale contient : (1) une partie à libération contrôlée qui comprend du mirabegron ou un sel de celui-ci pharmaceutiquement acceptable ; et (2) une partie à libération rapide qui comprend de la solifénacine ou un sel de celle-ci pharmaceutiquement acceptable, et un additif pharmaceutique pour améliorer la stabilité du mirabegron ou du sel de celui-ci pharmaceutiquement acceptable .
PCT/JP2015/055976 2014-02-28 2015-02-27 Composition pharmaceutique pour administration orale WO2015129893A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2014-037965 2014-02-28
JP2014037965A JP2017078023A (ja) 2014-02-28 2014-02-28 経口投与用医薬組成物

Publications (1)

Publication Number Publication Date
WO2015129893A1 true WO2015129893A1 (fr) 2015-09-03

Family

ID=54009205

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2015/055976 WO2015129893A1 (fr) 2014-02-28 2015-02-27 Composition pharmaceutique pour administration orale

Country Status (2)

Country Link
JP (1) JP2017078023A (fr)
WO (1) WO2015129893A1 (fr)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017186593A1 (fr) 2016-04-25 2017-11-02 Synthon B.V. Comprimés comprenant du mirabegron et de la solifénacine
EP3335700A1 (fr) * 2016-12-13 2018-06-20 Stada Arzneimittel Ag Forme pharmaceutique orale solide à libération prolongée comprenant du mirabegron
US10478399B2 (en) 2017-10-12 2019-11-19 Synthon B.V. Modified release tablet composition comprising mirabegron
US10543174B2 (en) 2016-04-25 2020-01-28 Synthon B.V. Modified release tablet composition comprising mirabegron
WO2020097328A1 (fr) * 2018-11-07 2020-05-14 Velicept Therapeutics, Inc Compositions pharmaceutiques à dose fixe pour le traitement d'une vessie hyperactive et d'états associés
US10751311B2 (en) 2014-12-03 2020-08-25 Velicept Therapeutics, Inc. Compositions and methods of using modified release solabegron for lower urinary tract symptoms
US11433054B2 (en) * 2017-07-14 2022-09-06 Daewoong Pharmaceutical Co., Ltd. Pharmaceutical preparation and preparation method therefor

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002255988A (ja) * 2001-03-05 2002-09-11 Hayashibara Biochem Lab Inc 糖質混合物とその製造方法並びに用途
WO2006070735A1 (fr) * 2004-12-27 2006-07-06 Astellas Pharma Inc. Préparation pharmaceutique granulaire stable de solifénacine ou de son sel
WO2008129937A1 (fr) * 2007-04-13 2008-10-30 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Structure multicouche pour applications buccales et son procédé de production
WO2010038690A1 (fr) * 2008-09-30 2010-04-08 アステラス製薬株式会社 Composition pharmaceutique à libération contrôlée
WO2010090172A1 (fr) * 2009-02-04 2010-08-12 アステラス製薬株式会社 Composition pharmaceutique pour une administration orale
JP2013535486A (ja) * 2010-08-03 2013-09-12 アルセレックス，インコーポレイテッド 過活動膀胱を治療するためのβ−３アドレナリン受容体アゴニストおよびムスカリン受容体アンタゴニストの組み合わせ
WO2014034860A1 (fr) * 2012-08-31 2014-03-06 アステラス製薬株式会社 Composition médicale administrée par voie orale

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002255988A (ja) * 2001-03-05 2002-09-11 Hayashibara Biochem Lab Inc 糖質混合物とその製造方法並びに用途
WO2006070735A1 (fr) * 2004-12-27 2006-07-06 Astellas Pharma Inc. Préparation pharmaceutique granulaire stable de solifénacine ou de son sel
WO2008129937A1 (fr) * 2007-04-13 2008-10-30 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Structure multicouche pour applications buccales et son procédé de production
WO2010038690A1 (fr) * 2008-09-30 2010-04-08 アステラス製薬株式会社 Composition pharmaceutique à libération contrôlée
WO2010090172A1 (fr) * 2009-02-04 2010-08-12 アステラス製薬株式会社 Composition pharmaceutique pour une administration orale
JP2013535486A (ja) * 2010-08-03 2013-09-12 アルセレックス，インコーポレイテッド 過活動膀胱を治療するためのβ−３アドレナリン受容体アゴニストおよびムスカリン受容体アンタゴニストの組み合わせ
WO2014034860A1 (fr) * 2012-08-31 2014-03-06 アステラス製薬株式会社 Composition médicale administrée par voie orale

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
TAKASHI MAKIMURA: "Stearic Acid Calcium no Kino to Shokuhin Bun'ya eno Oyo", FOOD CHEMICALS, vol. 22, no. 8, 2006, pages 38 - 43 *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10751311B2 (en) 2014-12-03 2020-08-25 Velicept Therapeutics, Inc. Compositions and methods of using modified release solabegron for lower urinary tract symptoms
WO2017186593A1 (fr) 2016-04-25 2017-11-02 Synthon B.V. Comprimés comprenant du mirabegron et de la solifénacine
US10543174B2 (en) 2016-04-25 2020-01-28 Synthon B.V. Modified release tablet composition comprising mirabegron
EP3335700A1 (fr) * 2016-12-13 2018-06-20 Stada Arzneimittel Ag Forme pharmaceutique orale solide à libération prolongée comprenant du mirabegron
US11433054B2 (en) * 2017-07-14 2022-09-06 Daewoong Pharmaceutical Co., Ltd. Pharmaceutical preparation and preparation method therefor
US10478399B2 (en) 2017-10-12 2019-11-19 Synthon B.V. Modified release tablet composition comprising mirabegron
WO2020097328A1 (fr) * 2018-11-07 2020-05-14 Velicept Therapeutics, Inc Compositions pharmaceutiques à dose fixe pour le traitement d'une vessie hyperactive et d'états associés

Also Published As

Publication number Publication date
JP2017078023A (ja) 2017-04-27

Similar Documents

Publication Publication Date Title
WO2015129893A1 (fr) Composition pharmaceutique pour administration orale
JP4688089B2 (ja) 放出制御医薬組成物
WO2014034860A1 (fr) Composition médicale administrée par voie orale
JP4868695B2 (ja) 崩壊性が良好な経口製剤
EP2116242B1 (fr) Nouvelle composition pharmaceutique
RU2580652C2 (ru) Фармацевтическая композиция для орального введения
JP2016188181A (ja) ミラベグロン含有放出制御錠剤
US20190046452A1 (en) Preparation containing 6,7-unsaturated-7-carbamoyl morphinan derivatives
NO20240297A1 (en) Co-crystals
US20140343076A1 (en) Pharmaceutical compositions of lurasidone
EP3697392B1 (fr) Comprimés comprenant de la tamsulosine et de la solifénacine
EP3886817A1 (fr) Composition pharmaceutique comprenant du ramipril et de l'indapamide
EP2839829B1 (fr) Comprimé à libération prolongée contenant de la lévodropropizine et procédé pour préparer celui-ci
EP2269586B1 (fr) Composition pharmaceutique comprenant du desloratadine
EP3996688B1 (fr) Préparation pharmaceutique
JP6123795B2 (ja) 放出制御医薬組成物
US10010529B2 (en) Extended release pharmaceutical formulations with controlled impurity levels
EP2468267B1 (fr) Composition de combinaison bicouche de vildagliptine et de gliclazide
US20230119355A1 (en) Pharmaceutical compositions of a kinase inhibitor
EP4255398A1 (fr) Préparation administrée par voie orale contenant de la solifénacine et de la tamsulosine
EP4395827A1 (fr) Co-cristaux
WO2016059192A1 (fr) Composition comprenant de l'odanacatib
KR20070023743A (ko) 메만틴의 조절된 방출 제제
WO2010070023A2 (fr) Formulations

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15754684

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 15754684

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: JP